静脉输注白蛋白在肾脏替代治疗中预防低血压与增强超滤的作用
本文综述静脉白蛋白用于肾脏替代治疗(KRT)期间预防或治疗低血压及增强超滤的理论益处与风险。低白蛋白血症在需KRT的AKI或维持性血透患者中常见且与不良预后相关,但现有证据显示白蛋白扩容效果不如预期,且缺乏支持常规使用的数据,需设计良好的试验验证。
要点
- 低白蛋白血症在KRT患者中常见,与并发症、透析中低血压和死亡强相关。
- 静脉白蛋白扩容效果不如依据其胶体渗透压所预期,且价格昂贵。
- 目前证据不足以支持KRT期间常规使用静脉白蛋白,需高质量试验验证。
核心结论
- 尽管静脉白蛋白在KRT患者中使用频繁且费用高昂,目前仅有极少数据支持其常规使用。
- 需要 adequately powered 的试验来评估静脉白蛋白在此场景中的疗效。
研究设计与样本
- 综述,探讨静脉白蛋白用于减轻透析中低血压和/或增强超滤的理论益处与风险,并总结相关证据。
- 纳入的研究涉及维持性血液透析患者和ICU中需KRT的危重AKI患者。
主要发现
- 低白蛋白血症在需KRT的AKI或维持性血透住院患者中常见,与并发症、透析中低血压和死亡强相关。
- 临床试验表明白蛋白的扩容效果远不如依据其胶体渗透压所预期。
- 近期一些研究提示高胶体渗透压白蛋白溶液可能诱发或加重脓毒症或休克患者的AKI,但支持该效应的总体证据薄弱。
临床怎么用
- 静脉白蛋白可用于预防或治疗低血压或增强液体清除,但该做法存在争议。
- 鉴于缺乏支持常规使用的数据,临床决策需权衡潜在获益与风险及高昂费用。
局限性
- 支持高胶体渗透压白蛋白溶液诱发或加重AKI的证据总体薄弱。
- 目前缺乏足够效能的试验来评估静脉白蛋白在KRT中的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among its many functions, owing to its oversized effect on colloid oncotic pressure, intravascular albumin helps preserve the effective circulatory volume. Hypoalbuminemia is common in hospitalized patients and is found especially frequently in patients who require KRT either for AKI or as maintenance hemodialysis. In such patients, hypoalbuminemia is strongly associated with morbidity, intradialytic hypotension, and mortality. Intravenous albumin may be administered in an effort to prevent or treat hypotension or to augment fluid removal, but this practice is controversial. Theoretically, intravenous albumin administration might prevent or treat hypotension by promoting plasma refilling in response to ultrafiltration. However, clinical trials have demonstrated that albumin administration is not nearly as effective a volume expander as might be assumed according to its oncotic properties. Although intravenous albumin is generally considered to be safe, it is also very expensive. In addition, there are potential risks to using it to prevent or treat intradialytic hypotension. Some recent studies have suggested that hyperoncotic albumin solutions may precipitate or worsen AKI in patients with sepsis or shock; however, the overall evidence supporting this effect is weak. In this review, we explore the theoretical benefits and risks of using intravenous albumin to mitigate intradialytic hypotension and/or enhance ultrafiltration and summarize the current evidence relating to this practice. This includes studies relevant to its use in patients on maintenance hemodialysis and critically ill patients with AKI who require KRT in the intensive care unit. Despite evidence of its frequent use and high costs, at present, there are minimal data that support the routine use of intravenous albumin during KRT. As such, adequately powered trials to evaluate the efficacy of intravenous albumin in this setting are clearly needed.
引用
- Hryciw N, Joannidis M, Hiremath S, et al. Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy. Clin J Am Soc Nephrol. 2020. PMID: 33115729. doi:10.2215/CJN.09670620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。